News

Ad hoc: Medigene secures funding for its cancer immunotherapy programmes through capital increase

Not for release, publication or distribution in the United States, Canada, japan or Australia 

  • Placement of all available new shares close to the current market price
  • Participation of new renowned institutional investors
  • Extension of cash reach at least until end of 2016

Martinsried/Munich, 15 July 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) completed the capital increase announced on 27 June 2014 for the funding of its cancer immunotherapy programmes. Gross proceeds of EUR 15.9 million were achieved by placing the maximum number of new shares and the issuance of convertible bonds. With that, the Company's cash reach will be extended at least until the end of 2016. A total of 3,016,082 new shares at a price of EUR 5.00 per share and convertible bonds divided into 818,658 notes in the nominal amount of EUR 1.00 per note were placed with existing Medigene shareholders and mainly new institutional investors. The offering of new shares was oversubscribed. With the capital increase, Medigene made full use of its remaining authorised capital currently available. 

By issuing 3,016,082 new shares from authorised capital, the share capital of Medigene AG increases by EUR 3,016,082 from EUR 10,889,950 to EUR 13,906,032. The gross proceeds generated from the issuing of new shares amounts to EUR 15,080,410. The new shares will be admitted to trading with ISIN DE000A11QVD8, securities identification number WKN A11QVD and stock exchange symbol MDG9 from 22 July up to 14 August 2014. From 15 August 2014 on, the new shares will have the same ISIN, securities identification number (WKN) and stock exchange symbol as the existing Medigene shares (ISIN: DE000A1X3W00, WKN: A1X 3W0, MDG1).

By issuing convertible bonds divided into 818,658 notes in the nominal amount of EUR 1.00 per note, Medigene achieved gross proceeds of EUR 818,658. The bond is structured as a zero coupon note. Subject to certain non-conversion periods the conversion right may be exercised by noteholders from 4 September 2014 until the maturity date at a conversion price of EUR 5.00 per share for conversion into up to 163,731 new shares. At the maturity date, which is two years after the issue date, the Company is entitled to require a mandatory conversion of the notes into shares.

Further information is provided with today's press release of Medigene AG at www.medigene.com.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com